A case of chronic myeloid leukemia with features of essential thrombocythemia in peripheral blood and bone marrow

Young Jae Byun, Byeong-Bae Park, Eun Sung Lee, Kyung Soo Choi, Dae Sung Lee
Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea

Abstract
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by overproduction of myeloid white blood cells. Philadelphia chromosome is an essential finding for CML diagnosis. Generally, a clinical diagnosis of essential thrombocytemia (ET) can be established from isolated marked thrombocytosis in peripheral blood. However, Philadelphia chromosome-positivity or bcr/abl rearrangement with isolated thrombocytosis should be diagnosed as CML, not ET, according to World Health Organization diagnostic criteria. Therefore, CML should not be excluded before confirming the presence of the Philadelphia chromosome or bcr/abl rearrangement in cases of isolated thrombocytosis in peripheral blood. We report a case of CML with clinical features of ET in a patient successfully treated with imatinib.

Key Words
Chronic myeloid leukemia, Philadelphia chromosome, Essential thrombocytemia

INTRODUCTION

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with clonal hyperproliferation of myeloid cells in the bone marrow. Clinical findings in chronic-phase CML include fatigue, decreased appetite, and splenomegaly, and hematological findings include leukocytosis, thrombocytosis, neutrophilia, and decreased leukocyte alkaline phosphatase (LAP) scores [1].

Isolated thrombocytosis is assumed to be essential thrombocytemia (ET) rather than chronic-phase CML in most cases. According to the 2008 World Health Organization diagnostic criteria, a diagnosis of ET is routinely made, if platelet counts exceed 450×10^9/L with proliferation of megakaryocytes in the bone marrow and JAK2 V617F mutation, excluding any evidence of other myeloproliferative neoplasms [2]. Therefore, cases of isolated thrombocytosis with Philadelphia chromosome or bcr/abl rearrangement, which are diagnostic markers for CML, should not be diagnosed as ET. In previous studies, however, patients have been diagnosed with Philadelphia chromosome-positive ET [3, 4]. Other contradictory results described them as variants of CML [5, 6].

We experienced a case of isolated thrombocytosis, initially suggestive of ET, positive for the Philadelphia chromosome and bcr/abl rearrangement. The patient was eventually diagnosed with chronic-phase CML, and was successfully treated with imatinib. Here, we report our case and include a literature review.

CASE REPORT

A 21-year-old woman presented to the outpatient clinic with lower abdominal pain. Seven days before presentation, she had a ruptured corpus luteal cyst, which was detected on abdominal computed tomography (CT) at another clinic. Her initial platelet count was estimated to be 3,777×10^9/L at our clinic. Because thrombocytosis appeared to be secondary to bleeding, the patient’s blood cell counts were only monitored during her clinical course. However, we decided to perform further evaluation because of thrombocytosis persisted for 2 weeks with no decrease in the platelet count. Her medical history was unremarkable, and she had no family history of hematologic disease or genetic disorders. Her vital
signs were normal at admission. Except for mild lower abdominal tenderness, the patient had no other positive findings on physical examination. Complete blood count (CBC) revealed a hemoglobin level of 10.1 g/dL, hematocrit level of 30.7%, white blood cell (WBC) count of 10×10^9/μL (differential count: neutrophils 63%, lymphocytes 33%, eosinophils 1%, basophils 3%, and monocytes 0%), and platelet count of 3,294×10^9/L. A serum biochemistry panel showed the following: total protein, 7.2 g/dL; albumin, 3.9 g/dL; total bilirubin, 1.2 mg/dL; aspartate aminotransferase, 11 IU/L; alanine aminotransferase, 13 IU/L; blood urea nitrogen, 6 mg/dL; creatinine, 0.6 mg/dL; lactic dehydrogenase, 410 IU/L; and C-reactive protein, 2.0 mg/dL. A peripheral blood smear showed thrombocytosis. In addition, serum iron level was 73 μg/dL, total iron binding capacity was 267 μg/dL, and ferritin level was 206.5 ng/mL. The patient had an LAP score of 127 points, which was within the normal range. Abdominal and pelvic CT showed a small amount of hemo-peritoneum resulting from the previous ruptured ovarian cyst. Bone marrow aspiration and biopsy revealed a high number of megakaryocytes, but no cells undergoing malignant transformation (Fig. 1, Fig. 2). A cytogenetic abnormality was detected with the karyotype 46,XX,t(9;22)(q34;q11.2) on bone marrow. We also observed a bcr/abl rearrangement in the bone marrow using reverse transcriptase PCR, which also showed amplified products from the b3a2 mRNA deletion in the major bcr gene. Results were negative for the JAK2 V617F mutation. Because the patient had isolated thrombocytosis (3,294×10^9/L), she was tentatively diagnosed with ET before the results of the cytogenetic and molecular studies were available. Hydroxyurea was administered to the patient at a dose of 2,000 mg/day for 14 days to lower her platelet count. A follow-up CBC showed persistent thrombocytosis, platelet counts of 2,206×10^9/L, and leukocytopenia (1.1×10^9/L). We stopped hydroxyurea and identified the Philadelphia chromosome and bcr/abl rearrangement, but no JAK2 V617F mutation. This led to the final diagnosis of chronic-phase CML, for which the patient received imatinib. In the 6 days following the treatment with imatinib, the patient’s platelet count normalized to 438×10^9/L. She is currently followed up to confirm complete molecular response against bcr/abl rearrangement. In the 3 months after treatment with imatinib, a major molecular response (3-log reduction of transcript levels) was observed.

**DISCUSSION**

Recently, a therapeutic advance in the treatment of CML was achieved with the advent of tyrosine kinase inhibitors for the bcr/abl protein. The long-term survival rate of patients with CML has improved to 89% [7]. To determine a distinctive diagnosis, we should distinguish CML from ET, which might have similar laboratory findings at initial diagnosis because of the different therapeutic approaches and clinical outcomes between the two diseases.

If severe thrombocytosis and hyperproliferation of megakaryocytes in the bone marrow occurs in the absence of splenomegaly, it is difficult to make a differential diagnosis between CML and ET without cytogenetic and molecular studies. Although the JAK2 V617F mutation is observed in approximately 50% of ET patients, JAK2 V617F mutation does not indicate a definitive diagnostic of ET, because ET should be confirmed with an exclusive diagnostic process. Therefore, the Philadelphia chromosome or bcr/abl rearrangement is a significant diagnostic tool for distinguishing CML from ET under these hematologically abnormal conditions.

A previous study showed mild basophilia and a Philadelphia chromosome in 1 of 121 patients with ET [8]. This patient had a Philadelphia chromosome and isolated thrombocytosis that progressed to the accelerated phase, which is similar to the clinical course observed in a patient with
CML. Patients with a Philadelphia chromosome and isolated thrombocytosis considered a variant of CML or an initial presentation of CML in the chronic phase were refractory to hydroxyurea, but showed improvement in symptoms and laboratory values after administration of imatinib [6].

Imatinib mesylate (Gleevec) is a \textit{bcr-abl} tyrosine kinase inhibitor and the primary treatment agent for patients with CML. By binding to \textit{bcr-abl} protein tyrosine kinase and inhibiting the \textit{bcr/abl} pathway, imatinib reduces the proliferation of \textit{bcr/abl}-positive CML cells [9]. In patients initially diagnosed with chronic-phase CML, the rate of complete cytogenetic remission has increased to 76.2\% in the imatinib era [10]. In addition, the overall survival rate significantly improved after treatment with imatinib in early-phase CML [7]. Therefore, imatinib is currently approved as a standard initial treatment for patients with chronic-phase CML.

In conclusion, our case indicates that CML could not be completely excluded until the presence of the Philadelphia chromosome or \textit{bcr/abl} rearrangement was confirmed, which would be clinically sufficient to diagnose CML.

\textbf{Authors' Disclosures of Potential Conflicts of Interest}

No potential conflicts of interest relevant to this article were reported.

\textbf{REFERENCES}

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.
2. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytopenia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7.
3. Kwong YL, Chiu EK, Liang RH, Chan V, Chan TK. Essential thrombocytopenia with \textit{BCR/ABL} rearrangement. Cancer Genet Cytogenet 1996;89:74-6.
4. Stoll DB, Peterson P, Exten R, et al. Clinical presentation and natural history of patients with essential thrombocytopenia and the Philadelphia chromosome. Am J Hematol 1988;27:77-83.
5. Emilia G, Marasca R, Zucchini P, et al. \textit{BCR-ABL} rearrangement is not detectable in essential thrombocytopenia. Blood 2001;97:2187-9.
6. Michiels JJ, Berneman Z, Schroyens W, et al. Philadelphia (Ph) chromosome-positive thrombocytopenia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocytopenia. Ann Hematol 2004;83:504-12.
7. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
8. Damaj G, Delabesse E, Le Bihan C, et al. Typical essential thrombocythaemia does not express \textit{bcr-abelson} fusion transcript. Br J Haematol 2002;116:812-6.
9. Savage DG, Antman KH. Imatinib mesylate—a new oral targeted therapy. N Engl J Med 2002;346:683-93.
10. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.